And Dr. Kumar, what would you add to that? The, this, this, this w- this focus on let's remember who these, who these medications were principally designed for.

So I agree with everything that Dr. DuChateau said about, um, who is supposed to take these medicines, patients with diabetes, patients with obesity or overweight with medical comorbidities.

The more time that passes and the more real world evidence we have, and we start learning about potential other benefits, reducing the risk of heart disease, treating fatty liver, treating sleep apnea, I think we're increasingly seeing a group of patients that don't fit the original criteria, are using it for their health and not necessarily vanity.

So I think there's also this, like, in between group of off-label use, not cosmetic use, but not the intended use.

Um, what do you make of that trend?

So I agree with everything Dr. Duchesse said about we're seeing a reduction in coverage, and often these coverage decisions are made at the level of the employer.

So employers are deciding that they don't wanna cover these medicines, because they're literally bankrupting small to medium-sized businesses.

And so people are going elsewhere for prescriptions.